Data from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

Abstract

<div>Abstract<p><b>Purpose:</b> Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating tumor DNA (ctDNA) is established in several solid malignancies as a minimally invasive tool to profile the tumor genome in real-time, but is critically underexplored in bladder cancer.</p><p><b>Experimental Design:</b> We applied a combination of whole-exome sequencing and targeted sequencing across 50 bladder cancer driver genes to plasma cell-free DNA (cfDNA) from 51 patients with aggressive bladder cancer, including 37 with metastatic disease.</p><p><b>Results:</b> The majority of patients with metastasis, but only 14% of patients with localized disease, had ctDNA proportions above 2% of total cfDNA (median 16.5%, range 3.9%–72.6%). Twelve percent of estimable samples had evidence of genome hypermutation. We reveal an aggressive mutational landscape in metastatic bladder cancer with 95% of patients harboring deleterious alterations to <i>TP53, RB1</i>, or <i>MDM2</i>, and 70% harboring a mutation or disrupting rearrangement affecting chromatin modifiers such as <i>ARID1A</i>. Targetable alterations in MAPK/ERK or PI3K/AKT/mTOR pathways were robustly detected, including amplification of <i>ERBB2</i> (20% of patients) and activating hotspot mutations in <i>PIK3C</i>A (20%), with the latter mutually exclusive to truncating mutations in <i>TSC1</i>. A novel <i>FGFR3</i> gene fusion was identified in consecutive samples from one patient.</p><p><b>Conclusions:</b> Our study demonstrates that ctDNA provides a practical and cost-effective snapshot of driver gene status in metastatic bladder cancer. The identification of a wide spectrum of clinically informative somatic alterations nominates ctDNA as a tool to dissect disease pathogenesis and guide therapy selection in patients with metastatic bladder cancer. <i>Clin Cancer Res; 23(21); 6487–97. ©2017 AACR</i>.</p></div>